Patients Experienced Pseudoprogression to Anti-PD1/PD-L1 Inhibitor Have Better Response Than Those Without in Lung Cancer

被引：0
|
作者：
Zhao, W. [1 ,2 ]
Zhou, F. [1 ,2 ]
Li, W. [2 ,3 ]
Qian, D. [1 ,2 ]
Zhang, J. [1 ,2 ]
Wu, F. [1 ,2 ]
Zhou, C. [1 ,2 ]
机构：
[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Pseudoprogression; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.10
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [31] Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study
    El Husseini, Kinan
    Piton, Nicolas
    De Marchi, Marielle
    Gregoire, Antoine
    Vion, Roman
    Blavier, Pierre
    Thiberville, Luc
    Baste, Jean-Marc
    Guisier, Florian
    CANCERS, 2021, 13 (19)
  • [32] PD-L1 expression in lung cancer
    Tang, Chad
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (11) : 3053 - 3055
  • [33] PD-L1 Expression in Lung Cancer
    Yu, Hui
    Boyle, Theresa A.
    Zhou, Caicun
    Rimm, David L.
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 964 - 975
  • [34] MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
    Alburquerque-Bejar, Juan J.
    Navajas-Chocarro, Pablo
    Saigi, Maria
    Ferrero-Andres, Ana
    Morillas, Juan M.
    Vilarrubi, Andrea
    Gomez, Antonio
    Mate, JoseL.
    Munoz-Marmol, Ana M.
    Romero, Octavio A.
    Blecua, Pedro
    Davalos, Veronica
    Esteller, Manel
    Pros, Eva
    Llabata, Paula
    Torres-Diz, Manuel
    Esteve-Codina, Anna
    Sanchez-Cespedes, Montse
    CELL REPORTS MEDICINE, 2023, 4 (04)
  • [35] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [36] Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer
    Kaufman, Bar
    Abramov, Orli
    Ievko, Anna
    Apple, Daria
    Shlapobersky, Mark
    Allon, Irit
    Greenshpan, Yariv
    Bhattachrya, Baisali
    Cohen, Ofir
    Charkovsky, Tatiana
    Gayster, Alexandra
    Shaco-Levy, Ruthy
    Rouvinov, Keren
    Livoff, Alejandro
    Elkabets, Moshe
    Porgador, Angel
    SCIENCE ADVANCES, 2023, 9 (21)
  • [37] Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy
    Cao, Xinyi
    Hu, Zhihuang
    Sheng, Xiangying
    Sun, Zhenyu
    Yang, Lijun
    Shu, Hong
    Liu, Xiaojing
    Yan, Guoquan
    Zhang, Lei
    Liu, Chao
    Zhang, Ying
    Wang, Huijie
    Lu, Haojie
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (08) : 1099 - 1107
  • [38] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [39] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [40] PD-1/PD-L1 and DNA Damage Response in Cancer
    Kciuk, Mateusz
    Kolat, Damian
    Kaluzinska-Kolat, Zaneta
    Gawrysiak, Mateusz
    Drozda, Rafal
    Celik, Ismail
    Kontek, Renata
    CELLS, 2023, 12 (04)
12345